Trial Profile
A Phase I, Randomized, Double-blind, Placebo Controlled, Ascending Dose Study in Healthy Chinese Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) Profile of Single and Multiple Ascending Oral Doses of TG-2349
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Furaprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Dongguan HEC TaiGen Biopharmaceuticals
- 07 Aug 2018 New trial record